These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19336931)

  • 1. The selectivity of beauveriolide derivatives in inhibition toward the two isozymes of acyl-CoA: cholesterol acyltransferase.
    Ohshiro T; Matsuda D; Nagai K; Doi T; Sunazuka T; Takahashi T; Rudel LL; Omura S; Tomoda H
    Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):377-81. PubMed ID: 19336931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
    Tomoda H; Doi T
    Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of microbial acyl-CoA: cholesterol acyltransferase inhibitors toward isozymes.
    Ohshiro T; Rudel LL; Omura S; Tomoda H
    J Antibiot (Tokyo); 2007 Jan; 60(1):43-51. PubMed ID: 17390588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity of pyripyropene derivatives in inhibition toward acyl-CoA:cholesterol acyltransferase 2 isozyme.
    Ohshiro T; Ohte S; Matsuda D; Ohtawa M; Nagamitsu T; Sunazuka T; Harigaya Y; Rudel LL; Omura S; Tomoda H
    J Antibiot (Tokyo); 2008 Aug; 61(8):503-8. PubMed ID: 18997389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New verticilides, inhibitors of acyl-CoA:cholesterol acyltransferase, produced by Verticillium sp. FKI-2679.
    Ohshiro T; Matsuda D; Kazuhiro T; Uchida R; Nonaka K; Masuma R; Tomoda H
    J Antibiot (Tokyo); 2012 May; 65(5):255-62. PubMed ID: 22415459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of acyl-CoA:cholesterol acyltransferase 2 isozyme by flavasperone and sterigmatocystin from Aspergillus species.
    Sakai K; Ohte S; Ohshiro T; Matsuda D; Masuma R; Rudel LL; Tomoda H
    J Antibiot (Tokyo); 2008 Sep; 61(9):568-72. PubMed ID: 19160525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of sterolO-acyltransferase 1 isozyme by beauveriolide III in intact cells.
    Ohshiro T; Kobayashi K; Ohba M; Matsuda D; Rudel LL; Takahashi T; Doi T; Tomoda H
    Sci Rep; 2017 Jun; 7(1):4163. PubMed ID: 28646165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
    Lada AT; Davis M; Kent C; Chapman J; Tomoda H; Omura S; Rudel LL
    J Lipid Res; 2004 Feb; 45(2):378-86. PubMed ID: 14617738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute stereochemistry of fungal beauveriolide III and ACAT inhibitory activity of four stereoisomers.
    Ohshiro T; Namatame I; Nagai K; Sekiguchi T; Doi T; Takahashi T; Akasaka K; Rudel LL; Tomoda H; Omura S
    J Org Chem; 2006 Sep; 71(20):7643-9. PubMed ID: 16995669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 1.
    Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Omura S; Tomoda H; Nagamitsu T
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1285-7. PubMed ID: 23369538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 3.
    Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Ōmura S; Tomoda H; Nagamitsu T
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3798-801. PubMed ID: 23711919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular target of rubimaillin in the inhibition of lipid droplet accumulation in macrophages.
    Matsuda D; Ohshiro T; Ohba M; Jiang W; Hong B; Si S; Tomoda H
    Biol Pharm Bull; 2009 Aug; 32(8):1317-20. PubMed ID: 19652367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compared with Acyl-CoA:cholesterol O-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol.
    Temel RE; Gebre AK; Parks JS; Rudel LL
    J Biol Chem; 2003 Nov; 278(48):47594-601. PubMed ID: 12975367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Biological Evaluation of Beauveriolide Analogues Bearing Photoreactive Amino Acids.
    Masuda Y; Aoyama K; Yoshida M; Kobayashi K; Ohshiro T; Tomoda H; Doi T
    Chem Pharm Bull (Tokyo); 2016 Jul; 64(7):754-65. PubMed ID: 27020600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells.
    Seo T; Oelkers PM; Giattina MR; Worgall TS; Sturley SL; Deckelbaum RJ
    Biochemistry; 2001 Apr; 40(15):4756-62. PubMed ID: 11294643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voluhemins, new inhibitors of sterol O-acyltransferase, produced by Volutella citrinella BF-0440.
    Ohshiro T; Morita H; Nur EAA; Hosoda K; Uchida R; Tomoda H
    J Antibiot (Tokyo); 2020 Nov; 73(11):748-755. PubMed ID: 32467602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical role for the histidine residues in the catalytic function of acyl-CoA:cholesterol acyltransferase catalysis: evidence for catalytic difference between ACAT1 and ACAT2.
    An S; Cho KH; Lee WS; Lee JO; Paik YK; Jeong TS
    FEBS Lett; 2006 May; 580(11):2741-9. PubMed ID: 16647063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform-specific inhibitors of ACATs: recent advances and promising developments.
    Ohshiro T; Tomoda H
    Future Med Chem; 2011 Dec; 3(16):2039-61. PubMed ID: 22098352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.
    Shibuya K; Kawamine K; Miura T; Ozaki C; Edano T; Mizuno K; Yoshinaka Y; Tsunenari Y
    Bioorg Med Chem; 2018 Aug; 26(14):4001-4013. PubMed ID: 29945757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation.
    Liu Y; Ding F; Deng L; Zhang S; Wu L; Tong H
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2403736. PubMed ID: 39316789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.